Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus TOLMETIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus TOLMETIN SODIUM.
ANAPROX DS vs TOLMETIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It has anti-inflammatory, analgesic, and antipyretic effects.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
400 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Terminal elimination half-life is approximately 4.5–6 hours (mean 5 hours); may be prolonged in elderly or patients with renal impairment
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal excretion (~90% as unchanged drug and conjugates), with fecal excretion (~10% as metabolites)
Category C
Category D/X
NSAID
NSAID